- Home
- PLUR vs TPST Comparison
PLUR vs TPST Comparison
Compare PLUR & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | TPST |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 30.9M |
| IPO Year | 2001 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PLUR | TPST |
|---|---|---|
| Price | $3.55 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $11.00 |
| AVG Volume (30 Days) | 7.7K | ★ 173.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,336,000.00 | $295,000.00 |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $1.50 |
| 52 Week High | $5.96 | $12.22 |
Technical Indicators
Market Signals| Indicator | PLUR | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 45.82 |
| Support Level | $3.50 | $1.57 |
| Resistance Level | $3.85 | $2.48 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 65.01 | 35.19 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.